Additionally, systemic administration of CXCL12 may lead to off‐target effects, such as counteracting tumor‐secreted CXCL12, highlighting the need for optimized delivery methods, such as localized administration, to improve therapeutic specificity and minimize side effects. Here, CXCL12 is linked to neoplasm.